SCOTT OSABUOHIEN: Open Payments
NPI 1376281477 · DRAPER, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$684 in 31 payments from 13 companies in 2025. Trend: 2023 $642 · 2024 $590 · 2025 $684
Food & beverage: $684
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $88 |
| ABBVIE INC. | 4 | $80 |
| Janssen Pharmaceuticals, Inc | 4 | $77 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Alkermes, Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $32 |
Products named: INGREZZA, FANAPT, VRAYLAR, SPRAVATO, REXULTI, CAPLYTA, AUSTEDO XR, ARISTADA.
Industry payments across UT — which companies pay providers there.
